T2 Biosystems Inc. (NASDAQ:TTOO) has a beta of 0.63. The stock’s Relative Strength Index (RSI) is 49.05, with weekly volatility at 9.23% and ATR at 0.36. The TTOO stock’s 52-week price range has touched low of $0.23 and a $3.79 high. Its shares traded lower over the last trading session, losing -10.95% on 02/22/21. The shares fell to a low of $2.51 before closing at $2.52. Intraday shares traded counted 8.12 million, which was 31.19% higher than its 30-day average trading volume of 11.80M. TTOO’s previous close was $2.83 while the outstanding shares total 147.79M.
Investors have identified the Diagnostics & Research company T2 Biosystems Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $386.01 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
T2 Biosystems Inc. (TTOO) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 51.45 million total, with 10.35 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -0.27 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on TTOO sounds very interesting.
Is the stock of TTOO attractive?
In related news, SVP, Operations, Barclay Alec sold 5,808 shares of the company’s stock in a transaction that recorded on Feb 24. The sale was performed at an average price of 0.82, for a total value of 4,763. As the sale deal closes, the General Counsel, Gibbs Michael Terrence now sold 5,808 shares of the company’s stock, valued at 4,763. Also, Chief Scientific Officer, Lowery Thomas J. sold 5,808 shares of the company’s stock in a deal that was recorded on Feb 24. The shares were price at an average price of 0.82 per share, with a total market value of 4,763. Following this completion of acquisition, the Chief Financial Officer, Sprague John M now holds 4,166 shares of the company’s stock, valued at 3,416. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.10%.
4 out of 5 analysts covering the stock have rated it a Buy, while 1 have maintained a Hold recommendation on T2 Biosystems Inc.. 0 analysts has assigned a Sell rating on the TTOO stock. The 12-month mean consensus price target for the company’s shares has been set at $3.18.